NewAmsterdam Pharma Company N.V. reported its financial results for the first quarter of 2026, revealing a revenue of $3.0 million, a slight increase from $2.978 million in the same period last year. The revenue for the current quarter was primarily generated from a supply agreement with A. Menarini International Licensing S.A., which was not present in the previous year. The company’s operating expenses decreased to $61.5 million from $71.9 million, leading to an operating loss of $58.4 million, an improvement from the $68.9 million loss reported in the first quarter of 2025.
The decrease in operating expenses was attributed to a reduction in research and development costs, which fell to $38.0 million from $44.8 million, largely due to the completion of Phase 3 clinical trials. Selling, general, and administrative expenses also decreased to $23.5 million from $27.2 million, reflecting a strategic shift in the classification of certain medical affairs costs to research and development. The net loss for the quarter was $48.4 million, compared to a loss of $39.5 million in the prior year, primarily driven by changes in fair value of warrants and foreign exchange losses.
In terms of operational metrics, NewAmsterdam Pharma's cash and cash equivalents stood at $457.6 million as of March 31, 2026, down from $490.0 million at the end of 2025. The company reported a total of 116.6 million ordinary shares outstanding, reflecting a slight increase from the previous quarter. The company continues to focus on advancing its lead product candidate, obicetrapib, which is undergoing multiple Phase 3 clinical trials aimed at addressing unmet needs in the treatment of cardiovascular diseases.
Looking ahead, NewAmsterdam Pharma is preparing for potential regulatory submissions for obicetrapib and its fixed-dose combination therapy with ezetimibe, with decisions from European regulators expected in the second half of 2026. The company plans to submit a New Drug Application in the U.S. shortly after these submissions. The ongoing clinical trials and the anticipated regulatory approvals are critical to the company’s strategy for commercialization and future revenue generation. However, the company acknowledges the inherent risks and uncertainties associated with drug development and market acceptance.
About NewAmsterdam Pharma Co N.V.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.